Rates of advance directives low among Australians; healthy seniors wanted for Alzheimer’s study; ageing well in CALD communities; call to reduce the disproportionate suffering of older persons in disasters.
Curtin University researchers have found that current methods for predicting the onset of Alzheimers disease are too simplistic and a broad approach is needed.
It’s not a cure but a new ‘food for special medical purposes’ (or FSMP) offers evidence based help with memory function for people in the early stages of Alzheimer’s disease.
A West Australian study investigating whether a testosterone and fish oil combination can prevent or postpone the onset of Alzheimer’s disease is seeking volunteers.
Doing two things at once is the focus of a Perth study which is looking at how mood or memory related conditions affect the ability to multitask.
Alzheimer’s Australia wants more than 100,000 Valentine’s Day campaign postcards, calling for dementia-specific government funding, to flood the letterboxes of federal parliamentarians. The V-day hitlist includes the PM herself, Tony Abbott and Penny Wong
A new WA study will investigate the link between dementia and sleep disturbances, and help those living with the disease and carers to get some much-needed shut-eye.
In the absence of more conclusive evidence, we should be careful not to over-emphasise the benefits of Alzheimer’s disease prevention strategies, an international expert has warned.
A partnership between Brisbane North Institute of TAFE and a group of aged care providers is increasing the skill level of the aged care workforce.
More than 500 Alzheimer’s Australia supporters marched on Parliament House in Canberra today demanding funding for dementia care and research. There were placards and a new Deloittes Access Economics report to support the case.
Around 1,500 concerned members of the community are planning to march on parliament and demand government action to restores dementia funding.
A large landmark study from the UK has found that the two antidepressants most commonly prescribed for people who have Alzheimer’s disease are no better than placebo and are linked to more side effects